JAK 1/2 Blockade in MDA5 Gain-of-Function
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Immunology"
DOI: 10.1007/s10875-018-0563-2
Abstract: To the Editor, Mendelian type I interferonopathies are an increasingly recognized cause of treatment-refractory multisystem inflammation [1]. Here we report the beneficial effect of the JAK 1/2 inhibitor ruxolitinib in an infant with progressive neurological… read more here.
Keywords: jak blockade; age; mda5 gain; blockade mda5 ... See more keywords